Treatment Access Solution

A collaboration with Celgene Thailand

Revlimid® (lenalidomide)

The Max Foundation partners with Celgene Thailand to increase access to Revlimid® (lenalidomide) through the Revlimid® Access Program (RAP) for multiple myeloma patients in Thailand who meet the medical criteria and program guidelines.

Contact us for more information about how to access Revlimid® for multiple myeloma patients in Thailand.

Return to Treatment Access Solutions

Follow the Patient Journey

Join Rosario as she shares her journey from cancer patient to advocate and leader.
See Rosario's Journey